Gluamet

GluaMet is a prescription oral medication that combines metformin hydrochloride and vildagliptin. It belongs to the biguanide and DPP‑4 inhibitor classes and is marketed in the European Union for type 2 diabetes mellitus. The fixed‑dose combination targets hepatic glucose production and incretin‑mediated insulin secretion, offering a dual mechanism of action in a single tablet. It is intended for use alongside diet and exercise as part of a diabetes care plan.

GluaMet is indicated for the treatment of adults with type 2 diabetes mellitus when diet, exercise, and monotherapy with either metformin or a DPP‑4 inhibitor do not provide adequate glycemic control.

- Adjunct to lifestyle modification for improved fasting plasma glucose. - Combined therapy to lower HbA1c in patients inadequately controlled on metformin alone. - Use in patients who require both hepatic glucose reduction and enhanced incretin response. - Suitable for individuals with renal function within metformin prescribing limits. - Can be part of a step‑wise treatment algorithm for type 2 diabetes.

The safety profile of GluaMet reflects the combined effects of metformin and vildagliptin, with adverse events ranging from mild gastrointestinal symptoms to rare but serious metabolic disturbances.

Common: - Nausea, vomiting, or abdominal discomfort. - Diarrhea or loose stools. - Upper respiratory tract infection symptoms. - Mild headache or dizziness. - Metallic taste in the mouth. - Indigestion or heartburn. - Transient loss of appetite. - Mild skin rash.

Serious: - Lactic acidosis, a rare but life‑threatening condition. - Severe hypoglycemia, especially when combined with insulin or sulfonylureas. - Pancreatitis presenting with abdominal pain and elevated enzymes. - Severe allergic reactions such as rash, swelling, or anaphylaxis. - Renal impairment leading to accumulation of metformin.

When prescribing GluaMet, clinicians should consider patient-specific factors and monitor for conditions that may increase the risk of adverse events or reduce therapeutic effectiveness.

- Assess renal function before initiating therapy and periodically thereafter. - Avoid use in patients with a history of lactic acidosis. - Use caution in individuals with hepatic impairment. - Do not initiate in patients with active pancreatitis. - Adjust dose in elderly patients or those with reduced kidney function. - Discontinue if severe hypoglycemia or signs of lactic acidosis occur. - Monitor blood glucose regularly to detect hypo‑ or hyperglycemia.

GluaMet may interact with other medicines, affecting glucose control or increasing the risk of side effects; reviewing a patient’s medication list is essential before starting therapy.

Avoid: - Concurrent use with other biguanides or high‑dose metformin. - Combination with insulin or sulfonylureas without dose adjustment. - Co‑administration with iodinated contrast agents in patients with renal impairment. - Use with strong CYP2C9 inhibitors that may affect vildagliptin metabolism. - Avoid use with alcohol excess, which can increase risk of lactic acidosis.

Use with caution: - Beta‑blockers may mask hypoglycemia symptoms. - Diuretics can alter electrolyte balance, influencing renal clearance. - Corticosteroids may raise blood glucose, requiring closer monitoring. - ACE inhibitors may affect renal function; monitor creatinine when combined.